| 臺大學術典藏 |
2022-09-06T07:43:16Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; MING-SHIANG WU; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-09-06T02:41:54Z |
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
|
Chia Y.M.F.; Teng T.-H.K.; Tay W.T.; Anand I.; MacDonald M.R.; Yap J.; Chandramouli C.; Richards A.M.; Tromp J.; Ouwerkerk W.; Ling L.H.; Lam C.S.P.; Hung C.-L.; Liew H.B.; Narasimhan C.; Ngarmukos T.; Park S.W.; Reyes E.; Siswanto B.B.; Shimizu W.; Zhang S.; Fan X.; Chen K.; Wu L.; Xie Y.; Jin Q.; Ling T.; Li X.; Zhou F.; Zhou Y.; Xu D.; Zhang H.; Su Y.; Chen X.; Qin S.; Wang J.; Gong X.; Wu Z.; Yu C.M.; Sastry B.K.S.; Gopi A.; Raghu K.; Sridevi C.; Kaur D.; Naik A.; Parikh K.; Chandarana A.; Shah U.; Chag M.; Baxi H.; Gupta S.; Bhatia J.; Khakhkhar V.; Sankhla V.; Patel T.; Kapoor V.; Wander G.S.; Tandon R.; Chopra V.; Kumar M.; Sethi H.J.S.; Verma R.; Mittal S.; Sawhney J.; Sharma M.K.; Purayil M.P.; Tedjokusumo P.; Martanto E.; Erwinanto, Munawar M.; Pambudi J.A.; Lukito A.; Pardede I.; Thengker A.; Damay V.; Danny S.S.; Surarso R.; Noda T.; Nakajima I.; Wada M.; Ishibashi K.; Kurita T.; Yasuoka R.; Asai K.; Murai K.; Kubota Y.; Izumi Y.; Ikeda T.; Hisatake S.; Kabuki T.; Kiuchi S.; Hagiwara N.; Suzuki A.; Suzuki T.; Hong S.K.; Lee S.; Soo L.D.; Kim D.-H.; Shim J.; Park S.-M.; Roh S.-Y.; Kim Y.H.; Kim M.; Choi J.-I.; Na J.O.; Rha S.W.; Seo H.S.; Oh D.J.; Park C.G.; Kim E.J.; Joung B.; Uhm J.-S.; Lee M.H.; Cho I.-J.; Park H.-N.; Park H.-W.; Cho J.-G.; Yoon N.; Lee K.; Kim K.H.; Kim S.H.; Saharudin S.; Beh B.C.; Lee Y.W.; Yen C.H.; Othman M.K.; Augustine A.-A.; Asnawi M.H.M.; Mojolou R.A.; Tan Y.Z.; Arbain A.N.; Wong C.K.; Omar R.; Ghazi A.M.; Khelae S.K.; Chew D.S.P.; Yap L.B.; Hussin A.; Muhammad Z.; Azmee M.G.; Abidin I.Z.; Zhudi A.S.B.M.; Sari N.A.M.; Sridhar G.S.; Zuhdi A.S.M.; Ismail M.D.; Ong T.K.; Cham Y.L.; Khiew N.Z.; Said A.B.; Fong A.Y.Y.; Amin N.H.M.; Seng K.C.; Tan S.K.; Yew K.L.; Santos J.; Lim A.; Lapitan R.; Andal R.; Lopez E.; Sim K.L.D.; Tan B.Y.; Lim C.P.; Teo L.L.Y.; Chan L.L.H.; Chai P.; Wong C.C.R.; Poh K.K.; Yeo P.S.D.; Lee E.M.; Loh S.Y.; Ching M.E.; Khoo D.Z.L.; Yew M.S.; Huang W.; Leong K.T.G.; See J.H.J.; Lim Y.B.; Tan S.; Yeo C.; Chai S.C.; Jaufeerally F.R.; Tulsidas H.; Aung T.; Ong H.Y.; Ling L.F.; Soon D.K.N.; Yeh H.-I.; Kuo J.-Y.; Yen C.-H.; Hwang J.-J.; Chien K.-L.; Su T.-C.; LIAN-YU LIN; Juang J.-M.; Lin Y.-H.; Chiang F.-T.; Lin J.-L.; Ho Y.-L.; Lee C.-M.; Lin P.-C.; Hung C.-S.; Chang S.-N.; Lin J.-W.; Hsu C.-N.; Yu W.-C.; Chao T.-F.; Sung S.-H.; Wang K.-L.; Leu H.-B.; Lin Y.-J.; Chang S.-L.; Huang P.-H.; Lo L.-W.; Wu C.-H.; Liang H.-Y.; Chang S.-S.; Hsiao L.-C.; Wang Y.-C.; Lu C.-R.; Wu H.-P.; Lin Y.-N.; Chen K.-W.; Lo P.-H.; Hsu C.-H.; Hsieh L.-C.; Chandavimol M.; Yingchoncharoen T.; Laothavorn P.; Tiyanon W.; Wongcharoen W.; Phrommintikul A.; on behalf of the ASIAN-HF Investigators |
| 臺大學術典藏 |
2022-09-02T02:56:45Z |
A randomized controlled trial of clinic-based and home-based interventions in comparison with usual care for preterm infants: Effects and mediators
|
Jeng S.-F.; Wu Y.-T.; Chen L.-C.; Yu Y.-T.; Li-Jung Fang, Hsu H.-C.; Yang M.-C.; Chiu N.-C.; Chen W.J.; SUSAN SHUR-FEN GAU; Wu Y.-C.; Leng C.-H.; Hsieh W.-S.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Hsu C.-H.; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N.; Chao Y.; Chen J.-S.; Bang Y.-J.; Bendell J.; Lee K.-H.; Wang Y.; Abdullah H.; Liu B.; Spahn J.; Hack S.P.; Verret W.; CHIH-HUNG HSU; Lee M.S. |
| 臺大學術典藏 |
2022-08-19T00:21:17Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Yeh K.-H.; Bu C.-F.; Lin C.-C.; Lu Y.-S.; Yang C.-H.; CHIUN HSU; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:15Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.; Wu C.-Y.; Chen J.-S.; Li C.-C.; Liu H.-T.; Hsu C.-H.; Lu Y.-S.; Yeh K.-H.; Yang C.-H.; Shen Y.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:21:12Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.; Cheng A.-L.; CHIUN HSU; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2022-08-19T00:21:10Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; CHIUN HSU; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:09Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; CHIUN HSU; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:08Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; CHIUN HSU; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:05Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; CHIUN HSU; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Cheng A.-L.; Ding Y.-H.; CHIUN HSU; Shao Y.-Y.; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:01Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Shao Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:00Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Hsu C.-H.; Hu F.-C.; CHIUN HSU; Yu C.-W.; Shen Y.-C.; Hsu C.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; CHIUN HSU; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.; Chang D.-Y.; Hu F.-C.; Shao Y.-Y.; CHIUN HSU; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shen Y.-C.; Hsu C.-H.; Cheng A.-L.; CHIUN HSU; Lin Z.-Z.; Lu L.-C.; Shao Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:51Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lai M.-S.; Yang J.C.-H.; Cheng A.-L.; Hsu C.-H.; Kuo R.N.-C.; Yeh Y.-C.; Shao Y.-Y.; CHIUN HSU; Shau W.-Y.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:44Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:42Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
CHIUN HSU; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H.; Guo J.-C.; Kuo T.-C.; Wu H.; Yang S.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:41Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:38Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Liu T.-H.; Shao Y.-Y.; Lu L.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; CHIUN HSU; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Tebbutt N.; Strickler J.; Stein S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Dev A.; Davis S.L.; Chung H.C.; Chen J.-S.; Chao Y.; Bendell J.; Bang Y.-J.; Lee K.-H.; He A.R.; Wang Y.; Liu B.; Abdullah H.; Hack S.P.; Spahn J.; Lee M.S.; Ryoo B.-Y.; Hsu C.-H.; Numata K.; Stein S.; Verret W. |
| 臺大學術典藏 |
2022-08-19T00:20:30Z |
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; Lee J.-M.; CHIUN HSU; Hsu C.-H.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-08-19T00:20:28Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.; CHIUN HSU; Lee J.-M.; Chao Y.; Shao Y.-Y.; Hsu C.-H.; Yang M.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:28Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Sun N.-Y.; CHIUN HSU; Cheng A.-L.; Shao Y.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.-H.; Hsu H.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:27Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Lin Z.-Z.; Hsu C.-H.; Liang P.-C.; Chen B.-B.; Shao Y.-Y.; CHIUN HSU; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:27Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Lin Z.-Z.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Shao Y.-Y.; Hsu C.-H.; CHIUN HSU; Liang P.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:26Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
CHIUN HSU; Shao Y.-Y.; Chen C.-H.; Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.-H.; Lin Z.-Z.; Lu L.-C.; Liu T.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:25Z |
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
|
Liang P.-C.; Liu T.-H.; Lu L.-C.; CHIUN HSU; Shao Y.-Y.; Chen B.-B.; Shih T.T.-F.; Shen Y.-C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:24Z |
AXL and MET in Hepatocellular Carcinoma: A Systematic Literature review
|
Huang Y.-H.; CHIUN HSU; Hsu C.-H.; Lin S.-M. |
| 臺大學術典藏 |
2022-08-12T06:29:09Z |
A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
|
Yeh K.-H.; Cheng A.-L.; Lin M.-T.; Hong R.-L.; Hsu C.-H.; Lin J.-F.; KING-JEN CHANG; Lee P.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2022-08-12T06:28:26Z |
P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
|
Liang J.-T.; Huang K.-C.; Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Wang S.-M.; KING-JEN CHANG |
| 臺大學術典藏 |
2022-08-12T06:28:23Z |
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection
|
Liang J.-T.; Huang K.-C.; Lai H.-S.; Lee P.-H.; Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Wang S.-M.; Tang C.; KING-JEN CHANG |
| 臺大學術典藏 |
2022-08-12T06:28:04Z |
Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin b
|
Huang T.-C.; Chang H.-Y.; Hsu C.-H.; Kuo W.-H.; KING-JEN CHANG; Juan H.-F. |
| 臺大學術典藏 |
2022-08-12T06:27:44Z |
Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change
|
Tyan S.-W.; Hsu C.-H.; Peng K.-L.; Chen C.-C.; Kuo W.-H.; Lee E.Y.-H.P.; Shew J.-Y.; KING-JEN CHANG; Juan L.-J.; Lee W.-H. |
| 臺大學術典藏 |
2022-08-09T03:50:41Z |
Self assembled gold and silver nanoparticulates on silicon nanotips as surface enhanced Raman active substrates
|
Chattopadhyay S.; Lo H.C.; Chen K.H.; Hsu C.H.; Chen L.C.; Chattopadhyay S.; Lo H.C.; Chen K.H.; Hsu C.H.; Chen L.C.; LI-CHYONG CHEN |
| 臺大學術典藏 |
2022-08-09T03:50:37Z |
Generally applicable self-masked dry etching technique for nanotip array fabrication
|
Hsu C.-H.; Lo H.-C.; Chen C.-F.; Wu C.T.; Hwang J.-S.; Das D.; Tsai J.; Chen L.-C.; Chen K.-H.; Hsu C.-H.; Lo H.-C.; Chen C.-F.; Wu C.T.; Hwang J.-S.; Das D.; Tsai J.; Chen L.-C.; Chen K.-H.; LI-CHYONG CHEN |
| 臺大學術典藏 |
2022-07-28T07:28:09Z |
Mitochondrial DNA methylation profiling of the human prefrontal cortex and nucleus accumbens: correlations with aging and drug use
|
Huang C.-H.; Chang M.-C.; Lai Y.-C.; Lin C.-Y.; Hsu C.-H.; Tseng B.-Y.; Hsiao C.K.; Lu T.-P.; Yu S.-L.; SUNG-TSANG HSIEH; Chen W.J. |
| 臺大學術典藏 |
2022-07-26T08:55:57Z |
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
|
Shao Y.-Y.; Kuo H.-Y.; YUNG-MING JENG; Wu Y.-M.; Wang H.-P.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-07-12T01:43:03Z |
The efficacy of acupuncture in managing patients with chronic prostatitis/chronic pelvic pain syndrome: A systemic review and meta-analysis
|
Chang S.-C.; Hsu C.-H.; Hsu C.-K.; Yang S.S.-D.; SHANG-JEN CHANG |
| 臺大學術典藏 |
2022-06-27T07:06:22Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; CHONG-JEN YU; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:00:26Z |
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
|
Hsu C.-H.; Tseng C.-H.; Chiang C.-J.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; CHONG-JEN YU; Tsai Y.-H.; Chen J.-S.; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; Lee W.-C.; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:25Z |
Influence of patient and provider factors on the workload of on-call physicians A general internal medicine cohort observational study
|
Hsu N.-C.; Huang C.-C.; Jerng J.-S.; Hsu C.-H.; Yang M.-C.; Chang R.-E.; Ko W.-J.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T06:59:33Z |
Incidence of chronic thromboembolic pulmonary hypertension in Taiwan
|
Liu H.-Y.; Lu T.-P.; Tao C.-W.; Wu Y.-J.; Huang W.-C.; Hsu C.-H.; Liao W.-C.; Hsu H.-H.; Lin M.-C.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-10T06:11:17Z |
Combination of 13-cis retinoic acid and interferon-�\ in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.; ZHONG-ZHE LIN; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:16Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
ZHONG-ZHE LIN; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
